Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (NASDAQ: BNTX) generates frequent news flow as a global next generation immunotherapy company focused on oncology, mRNA technologies and COVID-19 vaccines. Its updates often cover progress across a diversified oncology pipeline that includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies, as well as developments in its mRNA vaccine programs for infectious diseases.
Investors following BioNTech news can expect regular announcements on clinical trial milestones in major tumor types such as lung, breast, gynecologic, gastrointestinal and genitourinary cancers. Recent releases have highlighted late-stage data readouts and trial initiations for investigational agents like pumitamig (a PD-L1xVEGF-A bispecific antibody co-developed with Bristol Myers Squibb) and gotistobart (a CTLA-4–targeting Treg modulator), including Phase 2 and Phase 3 results in indications such as triple-negative breast cancer and squamous non-small cell lung cancer.
BioNTech’s news stream also includes corporate and financial updates, such as quarterly results, guidance changes, and details of its cash and investment position. The company reports on its COVID-19 vaccine franchise, including launches of variant-adapted vaccines for specific vaccination seasons, and comments on how vaccine market dynamics affect revenues.
Another recurring theme in BNTX news is strategic transactions and partnerships. BioNTech has announced an all-stock acquisition of CureVac N.V. to strengthen its position in mRNA design, delivery formulations and manufacturing, and regularly issues releases on its collaboration with partners including Bristol Myers Squibb, Duality Biologics, OncoC4, Pfizer and others.
This news page aggregates these developments in one place, allowing readers to track BioNTech’s clinical progress, partnership activity, financial disclosures and strategic updates over time.
BioNTech SE (Nasdaq: BNTX) announced that CEO and Co-founder Ugur Sahin will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 am ET. A live webcast of the presentation will be accessible on the Company’s website, with a replay available for 30 days post-conference.
BioNTech is a leading biopharmaceutical company specializing in innovative immunotherapies for cancer and other serious diseases. It develops mRNA vaccines and collaborates with major pharmaceutical partners, advancing its oncology pipeline and infectious disease therapies.
Pfizer and BioNTech announced an agreement with the European Commission to deliver over 200 million additional doses of their COVID-19 vaccine, COMIRNATY, in 2022. This brings the total planned doses for the year to more than 650 million. The contract will include potential vaccines adapted for the Omicron variant at no additional cost. Pfizer and BioNTech had previously agreed to supply 900 million doses to the EC for 2022 and 2023, with an option for up to an additional 900 million doses.
On December 9, 2021, Pfizer and BioNTech announced the FDA's Emergency Use Authorization (EUA) expansion for a COVID-19 vaccine booster for individuals aged 16 and older. The booster, administered at least six months after the primary series, boasts the same formulation and dosage strength as the initial doses. Phase 3 trial data showed a 95% relative vaccine efficacy after the booster. This authorization, significant amid the emergence of variants like Omicron, reinforces the companies' commitment to global vaccination efforts as they prepare a supplemental Biologics License Application.
The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine booster, now available for individuals aged 16 and older. Administered at least six months post-primary series, the booster has shown a 95% efficacy in combating symptomatic COVID-19 compared to non-booster recipients. Pfizer and BioNTech plan to submit a supplemental Biologics License Application to formalize this authorization. The companies will continue supplying vaccines under existing agreements with the U.S. government through April 2022.
BioNTech SE (Nasdaq: BNTX) has scheduled a digital press conference for December 8, 2021, at 3:00 PM CET to discuss initial laboratory study results regarding the impact of the Omicron variant on COVID-19 vaccine-induced immune responses. The conference will be conducted in English and streamed online, with no on-site attendance for journalists. Recordings and presentations will be available later on their website.
BioNTech is known for its development of mRNA-based therapies for cancer and infectious diseases, collaborating with various global pharmaceutical partners.
Recent preliminary laboratory studies have shown that three doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) effectively neutralize the Omicron variant, while two doses result in a significant reduction in neutralization titers. A third dose increases neutralizing antibodies by 25-fold, achieving comparable levels to those against the wild-type virus. The companies are also advancing a variant-specific vaccine for Omicron, expected to be ready by March 2022, without affecting their projected capacity of four billion doses for the year.
Pfizer and BioNTech announced that three doses of their COVID-19 vaccine effectively neutralize the Omicron variant, while two doses show significantly reduced effectiveness. A booster dose increases neutralizing antibody titers by 25-fold against Omicron, similar to the response against the wild-type virus. Despite two doses providing some protection against severe disease, a third dose is recommended for optimal protection. The companies are developing a variant-specific vaccine for Omicron, expected by March 2022, without impacting their production capacity of four billion doses in 2022.
BioNTech (Nasdaq: BNTX) and Pfizer announced a positive opinion from the European Medicines Agency's CHMP, recommending the use of their COVID-19 vaccine, COMIRNATY, for children aged 5 to under 12. This marks a significant step as it could be the first vaccine authorized in the EU for this age group. The recommendation is based on a Phase 2/3 trial involving approximately 4,500 children, showing a 90.7% efficacy rate in those without prior infection. A final decision from the European Commission is expected soon, impacting all EU member states.
The Pfizer-BioNTech COVID-19 vaccine has shown a remarkable 100% efficacy against COVID-19 in a longer-term analysis involving adolescents aged 12 to 15. The pivotal Phase 3 trial data indicated no serious safety concerns, reinforcing confidence in the vaccine's effectiveness and safety profile. The companies plan to utilize these findings to support full regulatory approval in the U.S. and globally, moving towards a supplemental Biologics License Application to expand approval for this age group. This analysis contributes substantially to the existing data supporting the continued use of the vaccine.
The Pfizer-BioNTech COVID-19 vaccine showed 100% efficacy in a longer-term analysis for adolescents aged 12-15, with no serious safety issues reported. This data supports submissions for full regulatory approval in the U.S. and globally. The analysis, part of a pivotal Phase 3 trial, indicated that 0 symptomatic COVID-19 cases occurred in vaccinated participants compared to 30 in the placebo group. The companies plan to submit this data for regulatory review to expand the vaccine's approval.